Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.61 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ending March 31, 2024. “It has been a remarkable first quarter of execution as we made progress across our TED and neonatal Fc receptor (FcRn) inhibitor programs,” said Steve Mahoney, Viridian President and Ch.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Multifamily owner-operator and investment manager Pacific Urban Investors (“Pacific”) has acquired Viridian, a 420-unit apartment community in Greenwood Village, CO. Viridian (the “Property”) is located in the Denver Tech Center, adjacent to thousands of high paying technology, financial services, telecommunications, and aerospace jobs. The acquisition marks Pacific's fourth investment in the Denver market with the firm's regional portfolio now totaling 884 units.

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights. The webcast can be accessed under “Events and Presentations” on the Investors section of the Viridian website at vir.

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

PHILADELPHIA , March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's shareholders. The investigation seeks to determine whether Viridian and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's shareholders in connection with recent corporate actions.

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

Genius Sports

SkyWater Technology

Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20.

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian w.

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. “Throughout 2023, we delivered important clinical results across our TED portfolio, marking significant progress for the company,” said Steve Mahoney, Viridian President.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer. “I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian's executive team ahead of an exciting set of milestones this year across our t.

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 30,000 shares of the company's common stock.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. Viridian is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. In addition, Viridian has granted the underwriters a 30-day option.

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that President and Chief Executive Officer, Steve Mahoney, will discuss the company's progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of Viridian's presentation at the J.P. Morgan Healthcare Conference, Mr. Mahoney will provide.

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company along with its upcoming corporate priorities at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT / 10:30am ET in San Francisco,.

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Shares of Viridian Therapeutics underperformed this year. Negative biotech sentiment was partly to blame, as well as Tepezza's Y/Y net sales declines, and some internal turmoil with two CEO changes. These events overshadowed many positive developments in the company's TED pipeline, and more recently, the pipeline expansion with two preclinical anti-FcRn candidates.

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the selection of VRDN-003 as its lead subcutaneous (SC) program for thyroid eye disease (TED) based on positive data from a Phase 1 clinical study in healthy volunteers. The data showed that VRDN-003 has an extended half-life of 40-50 days, about 4-5 times longer than VRDN-001 a.

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Arvinas Inc

Academy Sports and Outdoors

Boot Barn Hlds

CymaBay Therapeutics

Flywire Corp

Guardant Health Inc

Immunovant Inc

Privia Health Group

Rocket Pharma

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

Best Small-Cap Stocks to Buy for 2024 and Beyond

Viridian Therapeutics, Inc. stock has been on a downward trend since announcing complex data in July. The market may be wrong in its assessment. However, I have no big conviction as to market success, only trial success.

Viridian: Market May Be Wrong In Its Disapproval

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30 at 11:15am ET in Miami, Florida. A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors sect.

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $0.86 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023. “We are focused on driving execution of our potentially best-in-class anti-IGF-1R therapies to reach meaningful clinical readouts in our intravenous and subcutaneous TED franchise,”.

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:00 p.m. GMT in London, UK. A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors secti.

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical data on the company's pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO 2023), to be held November 3-6, 2023.

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Viridian Therapeutics Stock (VRDN)